

1614 JFW

Patent Application
Attorney Docket No. PC10228B

I hereby certify that this correspondence is being deposited with the United States Postal Service by First Class mail, addressed to the Commissioner for Patents, Alexandria, VA 22313-1450, on this 4th day of August, 2004.

By

Martha C. Sibilio

(Signature of person mailing)

Martha C. Sibilio

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Farzan Rastinejad et al. :

APPLICATION NO.: 09/863,976

: Examiner: Jerome Goldberg

FILING DATE: May 23, 2001

: Group Art Unit: 1614

TITLE: METHODS AND COMPOSITIONS :
FOR RESTORING
CONFORMATIONAL STABILITY OF
A PROTEIN OF THE P53 FAMILY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AND PETITION PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820/Form 1449 which lists additional references cited by the Applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

Copies of the cited references are found in the file of parent application Serial No. 09/443,542 which is also with the Examiner.


Since this Supplemental Information Disclosure Statement is being filed after the mailing of a first action on the merits herein, Applicant's hereby petition for consideration of the references under 37 CFR 1.97 (c) and enclose the **fee of \$180.00**.

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445. A prompt and favorable response is earnestly solicited. A duplicate copy of this paper is enclosed for accounting purposes.

Date: _____


8/4/04

Respectfully submitted,



E. Victor Donahue
Attorney for Applicant(s)
Reg. No. 35,492


Pfizer Inc
Patent Department,
150 East 42nd Street, 5th floor
New York, NY 10017
(212) 733-2739



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10228B	SERIAL NO. 09/863,976
	APPLICANT FARZAN RASTINEJAD, et al.	
	FILING DATE May 23, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCL ASS	FILING DATE IF APPROPRIATE
		5	9	0	0	3	6	0	5/4/99	Welch, et al.			
		6	2	7	0	9	5	4	8/7/2001	Welch, et al.			
		6	3	5	9	0	0	0	3/19/2002	Jiang, et al.			
		6	3	7	2	7	8	5	4/16/02	Huang			
		6	3	8	4	0	4	9	5/7/02	Camden			
		6	3	8	7	6	7	3	5/14/02	Evans, et al.			
		6	3	8	7	9	0	3	5/14/02	Dinsmore, et al.			
		6	3	8	8	1	3	1	5/14/02	Medina, et al.			
		6	3	9	1	8	8	8	5/21/02	Gleich			
		6	3	9	1	3	0	2	5/21/02	Wallace, et al.			
		6	3	9	1	9	1	3	5/21/02	Pagé, et al.			
		6	3	9	1	8	5	3	5/21/02	Greene, et al.			
		6	3	9	1	9	1	6	5/21/02	Dai, et al.			
		6	3	9	2	0	6	3	5/21/02	Ali, et al.			
		6	3	9	5	7	2	9	5/28/02	Ferzaz, et al.			
		6	3	9	5	7	4	9	5/28/02	Li, et al.			
		6	3	9	5	7	7	1	5/28/02	Ramados, et al.			
		6	3	9	9	5	8	3	6/4/02	Ylihonko, et al.			
		6	3	9	9	5	9	8	6/4/02	Pikul, et al.			
		6	3	9	9	6	3	8	6/4/02	Vite, et al.			
		6	3	9	9	6	5	3	6/4/02	Henke			
		6	3	9	9	6	4	7	6/4/02	Kalgutkar, et al.			
		6	4	0	3	5	5	4	6/11/02	Strelchenok, et al.			
		6	4	0	3	5	6	9	6/11/02	Achterrath			
		6	4	0	3	5	9	2	6/11/02	Howard			
		6	4	0	3	6	2	5	6/11/02	Nagao, et al.			
		6	4	0	6	6	9	9	6/18/02	Wood			
		6	4	1	0	0	2	9	6/25/02	Mukhopadhyay, et al			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	0	2	2	4	6	9	2	3/28/02	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			"Strategies For Manipulation the p53 pathway in treatment of human cancer" T.R. Hupp, et al. Biochem J. (2000), 352, pgs 1-17
			"Restoration of the tumor suppressor function to mutant p53..." V. Bykov, et al. Nature Medicine, Vol. 8, No. 3, March 2002
			"P53 and IGFBP-3: Apoptosis and Cancer Protection" A. Grimberg, Molecular Genetics & Metabolism. 70, pgs 85-89, 2000
			"New Insights into p53 Regulation & Gene Therapy for Cancer" Alain G. Zeimet, et al. Biochemical Pharmacology, Vol 60, pp 1153-1163, 2000
			"Lucilactaene, a New Cell Inhibitor in p53-Transfected Cancer Cells" Riken, et al., Journal of Antibiotics, Vol. 54, No. 10, pp. 850-854, Oct. 2001,
			"Pharmaceutical Rescue of Mutant p53 Conformation & Function" Barbara Foster, et al. Science, Vol. 286, 12/24/99, pp2507-2510
			"Crystal Structure of a p53 Tumor Suppressor-DNA Complex...", Yunje Cho, et al., Science, Vol. 265, 7/15/94, pp 346-355
			"The Emerging p53 Gene Family" William G. Kaelin, Jr., Jour. National Cancer Inst., Vol. 91, No. 7, 4/7/99, pp594-598
			"Chemotherapeutic Targeting of p53", Martin L. Smith, et al, Cancer Biology & Therapy, Vol. 1, pp1,2, 2001
			"Rescuing the Function of Mutant p53" Alex N. Bullock, et al., Nature Reviews-Cancer, Vol.1, Oct. 2001, pp68-76
			"Oncogenic Mutations of the p53 Tumor Suppressor:"...A. Sigal, et al., Cancer Research, 60, 6788-6793, 12/15/2000
			"The Effects of wild-type p53 tumor suppressor activity..." C. Cadwell, et al. Gene 277 (2001) pp 15-30

EXAMINER

DATE CONSIDERED

Jerome Goldberg

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

